在肝细胞癌门诊实施姑息治疗——原发性肝癌加速转化研究(APRICA)随机对照姑息治疗试验的研究方案
该试验采用实用整群随机对照设计,以肝细胞癌门诊服务为整群,纳入BCLC A期有活动性肿瘤或当前/既往BCLC B或C期患者,排除BCLC D期。干预组对肝脏特异性ESAS任一症状评分≥5分的患者转诊姑息治疗医师会诊,主要临床结局为3个月内所有评分≥5分症状改善50%,主要实施结局为≥80%就诊患者记录肝脏特异性ESAS。
要点
- 干预组对肝脏特异性ESAS任一症状评分≥5分的患者转诊姑息治疗医师会诊。
- 主要临床结局为3个月内所有评分≥5分症状改善50%。
- 主要实施结局为≥80%就诊患者记录肝脏特异性ESAS。
核心结论
- 该试验将揭示更早的姑息治疗介入是否显著减轻肝细胞癌相关症状负担。
- 若发现有效,更早实施姑息治疗会诊应被纳入肝细胞癌治疗指南。
研究设计与样本
- 实用整群随机对照试验,以门诊肝细胞癌服务为整群。
- 招募BCLC A期有活动性肿瘤或当前/既往诊断BCLC B或C期(无论肿瘤活动性)的肝细胞癌患者。
- 排除BCLC D期患者,因该组姑息治疗为标准治疗(SOC)。
- 整群站点随机分为研究干预组或对照组,对照组患者按SOC管理。
- 所有参与者均在常规门诊预约时完成肝脏特异性埃德蒙顿症状评估量表(ESAS)和欧洲癌症研究与治疗组织生活质量问卷。
关键数值与推荐
- 干预组转诊姑息治疗医师的阈值为肝脏特异性ESAS任一症状评分≥5分。
- 主要临床结局为3个月内所有评分≥5分症状改善50%。
- 主要实施结局为≥80%就诊参与者记录肝脏特异性ESAS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integration of symptom and palliative care for people with advanced cancer is established in many tumour types, but its role in people with hepatocellular carcinoma (HCC) has not been clearly defined. This study aims to evaluate the clinical and cost effectiveness of an intervention involving a suite of strategies designed to assess and treat palliative care symptoms and needs in adult outpatients with HCC attending four New South Wales (NSW) metropolitan tertiary hospitals. METHODS: This trial will use a pragmatic cluster-based randomised-controlled design, with ambulatory HCC services as the clusters. HCC patients will be recruited if they have Barcelona Clinical Liver Cancer (BCLC) stage A disease with active tumour or a current or prior diagnosis of BCLC stage B or C disease regardless of tumour activity. Patients with BCLC stage D disease will be excluded as palliative care is the standard of care (SOC) in this group. Cluster sites will be randomised to the study intervention or control where patients are managed according to SOC. All participants will complete the liver-specific Edmonton Symptom Assessment Scale (ESAS) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire at regular ambulatory clinic appointments. At intervention sites, patients scoring ≥ 5 on any liver-specific ESAS symptom will be referred to palliative care physicians for consultation. The primary clinical outcome will be improvement in all symptoms scored ≥ 5 on the liver-specific ESAS by 50% within 3 months and the primary implementation outcome will recording the liver-specific ESAS in ≥ 80% of all participants attending clinic appointments. Caregivers of patients enrolled in the trial will be invited to perform Carer Support Needs Assessment Tool at each appointment. DISCUSSION: This trial will inform if earlier palliative care involvement significantly reduces the symptom burden associated with HCC. If found to be effective, earlier implementation of palliative care consultation should be included in HCC treatment guidelines. TRIAL REGISTRATION: ACTRN12623000010695. Registered on September 1, 2023.
引用
- Gofton C, Di Bartolomeo A, Boutros R, et al. Implementing palliative care in hepatocellular carcinoma ambulatory clinics-study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trial. Trials. 2024. PMID: 39506822. doi:10.1186/s13063-024-08603-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。